secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alzamend Neuro, Inc. (ALZN)
CIK:        0001677077
Form:       8-K
Filed at:   2025-11-18T23:59:59+00:00
Accession:  0001214659-25-016885
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alzamend Neuro director Andrew H. Woo, M.D., Ph.D. passed away on Nov. 14, 2025
-------------------------------------------------------------------------------

- Andrew H. Woo served as a director since the company's IPO in June 2021.
- William B. Horne, Chairman, expressed condolences; Woo is succeeded by no replacement yet.
- No other material events reported; financial statements not affected.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1677077/000121465925016885/0001214659-25-016885-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1677077/000121465925016885/x11172508k.htm
  HTML page:      https://secwatch.observer/filing/0001214659-25-016885

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer